The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to share that long-time member, and seasoned healthcare executive Rani Khetarpal, MBA, has been announced as President of its ...

Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against ...

RANI READ THE FULL RANI RESEARCH REPORT On May 13 th Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported first quarter 2025 results. Year to date, Rani has updated investors on ProGen’s PG102 ...

Contract Revenue for the three months ended March 31, 2025 were $0.2 million and was attributable to evaluation services performed for a customer. There was no contract revenue for the same period in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...

Please go ahead. Thank you, Operator. Please turn to Slide 2. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford.

March 31, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...

March 26, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...

SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral ...